Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors.

Next Previous
Trial Profile

An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trebananib (Primary) ; Bevacizumab; Motesanib; Sorafenib; Sunitinib
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Amgen

    • Most Recent Events

    • 06 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 27 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 May 2010 Planned end date changed from 1 Aug 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top